# Effects of the primary lung infection on outcomes in patients with severe ARDS treated with ECMO: a retrospective analysis

## TL;DR

This study finds that the type of lung infection in ARDS patients on ECMO affects outcomes differently, suggesting the need for tailored treatment approaches.

## Contribution

The study identifies etiology-specific differences in outcomes and predictors of mortality in infectious ARDS patients treated with ECMO.

## Key findings

- Non-Covid ARDS patients had higher disease severity but lower mortality compared to Covid-19 ARDS patients.
- Clinical factors like age and SOFA score predicted mortality in Covid-19 ARDS but not in Non-Covid ARDS.
- Blood transfusion strategies had different impacts on mortality depending on the ARDS etiology.

## Abstract

Acute respiratory distress syndrome (ARDS) requiring veno-venous extracorporeal membrane oxygenation (vvECMO) remains associated with high mortality. Whether etiology-based differentiation within infectious ARDS improves prognostic and therapeutic precision remains unclear. This study compared vvECMO-treated ARDS patients with different pulmonary infections to identify clinically relevant etiology-specific differences.

The retrospective single-center cohort study included adult patients who received vvECMO for severe infectious pulmonary ARDS between 2014 and 2021. Patients were categorized into Covid-19 (n = 48) and Non-Covid (n = 44). Clinical parameters, disease progression, treatment, and outcomes were compared. Cox and modified Poisson regression analyses identified predictors of ICU mortality.

Non-Covid ARDS patients had greater disease severity at ECMO initiation, although mortality was lower: SOFA score (15.7 vs. 13.7; p = 0.003); PRESERVE score (3.73 vs. 2.73; p = 0.004). In Covid-19 ARDS, age ≥60 years (RR 1.62), early SOFA score worsening (RR 1.17), new renal replacement therapy (RR 1.60), and septic shock (RR 3.33) were associated with increased mortality, whereas these factors were not predictive in Non-Covid ARDS. Red blood cell transfusion was associated with reduced mortality in both groups (HR 0.96 and 0.95), while fresh frozen plasma transfusion increased mortality exclusively in Covid-19 ARDS (HR 1.09). A rising SOFA score within 5 days after ECMO initiation predicted mortality only in the Covid-19 cohort (RR 1.17).

Even within primary infectious pulmonary ARDS, substantial heterogeneity exists. The underlying infection critically affects the prognostic value of clinical parameters, organ dysfunctions, and scoring systems in vvECMO-treated patients. Considering ARDS etiology may improve risk stratification and guide individualized therapy.

German Clinical Trials Register (DRKS00027856), https://drks.de/search/en/trial/DRKS00027856.